December 27, 2025
CRISPR or it didn't happen
Scientists Edited Genes Inside a Living Person for First Time, Saved His Life
Internet cheers miracle baby, then fights over FDA secrets, gold glitter, and credit
TLDR: Doctors used an in-body gene edit to fix a newborn’s deadly ammonia disorder, and he improved after three doses. Commenters are split between awe and skepticism, probing FDA transparency, what truly made this possible now, and whether attacks on universities threaten the public research behind future lifesaving cures
A real-life medical drama: a newborn, KJ, was born with a rare condition that lets toxic ammonia build up, too small for a transplant. Doctors rolled out a first-ever in-body gene fix—CRISPR—like microscopic repair crews, and after three doses, KJ improved. The internet exploded with hope and side-eye. Commenters like gavinray dropped the NEJM study receipts, while others demanded transparency, with lysace asking, “Are the approval documents public?” A wave of how-did-this-happen-now skepticism hit: qnleigh poked at the “gold nanoparticles” mention, noting those aren’t new, so what’s the real breakthrough?
Then came the memes: dlcarrier invoked the YouTuber who “edited himself” for lactose tolerance, sparking jokes about “milk DLC” and whether human patches expire. Policy watchers like gigatexal made it political, warning that attacks on universities could choke off the decades of research that made this miracle possible. In plain English: CRISPR is a tool that can cut and fix DNA, and “in vivo” means doctors did it inside KJ’s body, not in a dish. Big cheers for a saved baby, big questions about safety, off-target mistakes, and who gets credit—public labs or private companies. The vibe: science just pulled off a miracle; the comments turned it into a courtroom drama
Key Points
- •A newborn with severe CPS1 deficiency received a custom in vivo CRISPR gene therapy developed by a U.S. multi-institution team.
- •The case is detailed in the New England Journal of Medicine and is presented as the first bespoke in vivo gene-editing treatment in a living person.
- •The infant, too young for a liver transplant, was maintained on a protein-free diet during the six-month therapy development period.
- •Treatment began on February 25; after three doses, the patient showed significant clinical improvement.
- •Researchers cited decades of gene-editing progress and collaboration as key to enabling this rapid, patient-specific intervention.